EmVenio Research Triumphs at the 2025 Vaccine Industry Excellence Awards in D.C.

EmVenio Research Wins Prestigious Award

On April 22, 2025, during the World Vaccine Congress held in Washington, D.C., EmVenio Research earned the distinction of being named the Best Clinical Trial Company at the 2025 Vaccine Industry Excellence Awards. This accolade is a significant recognition for organizations that excel in clinical development needs through thorough assessments of their programs.

EmVenio Research has demonstrated exceptional capability in handling diverse clinical trials for vaccines, showcasing rapid recruitment rates as well as high retention levels for study subjects. Their dedication to improving patient access and inclusion in vaccine research underscores their innovative approach to clinical trials.

Thad Wolfram, the Chief Strategy Officer at EmVenio and PCM Trials, articulated the significance of this award, stating, "Winning at the ViE Awards is a testament to EmVenio's dedication to patient access and inclusion in vaccine research. Our team is honored to be recognized by the World Vaccine Congress among a prestigious group of innovative researchers and peers."

The company is currently engaged in an ongoing Flu Vaccine trial that integrates clinical research sites with mobile visit capabilities, enhancing accessibility for participants. This effort aligns with EmVenio's overarching goal of providing equitable access to clinical trials. Notably, in their vaccine studies, the representation of participants from historically underrepresented racial and ethnic backgrounds is impressive, accounting for 51.3%. This achievement significantly surpasses the industry benchmark of 25%.

Additionally, EmVenio has maintained a remarkably low dropout rate of below 1% out of 104 patients randomized and 594 total study visits conducted, significantly lower than the industry average of roughly 18%. This commitment to inclusivity and equal representation is setting a new standard in the realm of impactful clinical research.

Throughout its brief yet significant two-year history, EmVenio Research has contributed to 27 infectious disease studies across seven indications including COVID-19, Respiratory Syncytial Virus (RSV), pneumococcal, and flu vaccine trials. The company successfully recruited up to 46% of trial participants identifying as a diverse ethnicity, achieving 98.5% of its recruitment goals while retaining 98% of participants throughout the studies.

EmVenio Research operates as a part of PCM Trials and is committed to expanding its network of clinical trial sites strategically positioned in underrepresented communities to engage a more diverse patient demographic. Their extensive global network consists of highly skilled clinicians, leading principal investigators, and state-of-the-art research facilities, which enables them to deliver high-quality clinical research services while minimizing the burden on patient participation.

For those looking to learn more about EmVenio Research, their website, emvenio.com, provides additional information about their commitment to inclusivity and their ongoing work in the field of clinical trials.

EmVenio’s achievement at the ViE Awards not only reflects its dedication to advancing public health but also emphasizes the importance of diverse representation in clinical research—a crucial element in developing effective vaccines for all populations.

In conclusion, as EmVenio Research continues to break barriers in clinical trials and vaccine research, the company stands out as a leader in fostering inclusivity, setting a new benchmark for the industry to follow.